Eye and Adnexa Cancer

Eye and adnexa cancers (ICD-10 C69) include malignancies arising from the globe (eyeball) and all its surrounding structures. The major types are: uveal melanoma (arising from the pigment layer inside the eye — the most common primary intraocular cancer in adults); retinoblastoma (the most common intraocular cancer of children, arising from the retina); conjunctival melanoma and squamous cell carcinoma (arising from the conjunctival surface); orbital tumours including lymphoma, rhabdomyosarcoma, and lacrimal gland carcinoma; and eyelid cancers including sebaceous carcinoma and Merkel cell carcinoma. Each is a biologically distinct disease requiring specialist management.

Yes — in the vast majority of cases when managed at a specialist ocular oncology centre. Proton beam radiation therapy achieves local tumour control rates exceeding 95% while preserving the eye and useful vision in most patients. Brachytherapy plaque (a radioactive disc sutured to the sclera over the tumour) is an alternative for smaller tumours. Enucleation — surgical removal of the eye — is reserved for cases where the tumour is too large for radiation to preserve vision, where glaucoma from the tumour cannot be controlled, or where the patient prefers surgery. Any recommendation for enucleation should be confirmed by a second opinion from a specialist ocular oncology centre with proton therapy expertise.

Tebentafusp is the first systemic therapy to demonstrate an overall survival benefit in metastatic uveal melanoma — a disease where conventional chemotherapy and standard checkpoint inhibitors had previously failed to improve survival. It is a bispecific T-cell engager (ImmTAC) that redirects T cells to kill uveal melanoma cells by targeting the gp100 antigen presented on the cell surface. Eligibility is restricted to two criteria: HLA-A*02:01-positive genotype (present in approximately 45–50% of Caucasian patients) and GNAQ/GNA11-mutant uveal melanoma histology. HLA typing is performed by a blood test before treatment initiation. Tebentafusp is approved in the US and EU and available at specialist melanoma and ocular oncology centres.

Retinoblastoma can be hereditary or sporadic. Approximately 40% of cases are hereditary — caused by a germline mutation in one copy of the RB1 gene (the "first hit"). These children develop bilateral multifocal retinoblastoma and have a significantly elevated risk of other cancers throughout life, including osteosarcoma, soft tissue sarcoma, and melanoma. The remaining 60% are sporadic — caused by two somatic RB1 mutations in a single retinal cell. All children with retinoblastoma should have germline RB1 testing, and all siblings and children of RB1 carriers require ophthalmologic screening from birth to detect retinoblastoma at its earliest, most treatable stage.

The white eye reflex — known medically as leukocoria — is the most common first sign of retinoblastoma in children. In normal eyes, the pupil appears red in flash photographs due to reflection from the blood-rich retina. When a retinoblastoma tumour occupies the space behind the pupil, the flash reflects off the white tumour surface instead, producing a white or yellow-white pupillary reflex visible in photographs. Any child with a white pupillary reflex — whether noticed by a parent, photographed incidentally, or identified at a routine check — requires urgent ophthalmology assessment within days. Leukocoria is a paediatric emergency; prompt diagnosis and treatment are essential for life and vision preservation.

Conjunctival melanoma arises from the conjunctiva — the clear membrane covering the white of the eye and inner surface of the eyelids. It is biologically similar to mucosal and cutaneous melanoma, with BRAF mutations in approximately 30% of cases, KIT and NRAS mutations in additional subsets, and sensitivity to BRAF-targeted therapy and anti-PD-1 immunotherapy in the metastatic setting. Uveal melanoma, by contrast, arises from inside the eye (from the uveal tract — choroid, ciliary body, iris) and is driven by GNAQ/GNA11 mutations — making it biologically unrelated to conjunctival, mucosal, or cutaneous melanoma. Treatment approaches for the two are entirely different: conjunctival melanoma follows mucosal melanoma protocols; uveal melanoma has its own dedicated regimen with tebentafusp.

BAP1 tumour predisposition syndrome is a hereditary cancer predisposition syndrome caused by germline mutations in the BAP1 gene (BRCA1-associated protein-1). Individuals with this syndrome have a markedly elevated lifetime risk of uveal melanoma (often at a younger age than sporadic cases), mesothelioma, renal cell carcinoma (clear cell type), and cutaneous melanoma. BAP1 loss in a uveal melanoma specimen should prompt germline testing. A positive germline result means the patient and their first-degree relatives (parents, siblings, children) should undergo genetic counselling and enter a cancer surveillance programme covering all BAP1-associated cancers. Specialist hereditary cancer genetics services manage this evaluation.

Yes — sebaceous carcinoma of the eyelid is one of the most commonly misdiagnosed malignancies in ophthalmology, frequently mistaken for a chalazion (blocked Meibomian gland), blepharitis, or chronic conjunctivitis. Any eyelid swelling that recurs after drainage, does not resolve with standard treatment, is associated with loss of eyelashes, causes eyelid thickening or distortion, or is accompanied by a chronic unilateral conjunctivitis-like condition must be biopsied to exclude sebaceous carcinoma. The key risk factor to recognise is Muir-Torre syndrome — sebaceous carcinomas associated with germline mismatch repair deficiency also increase the risk of colorectal, endometrial, and other cancers.

Yes. Active trials are enrolling patients across several subtypes. For uveal melanoma: combination tebentafusp trials, PARP inhibitor trials in BAP1-deficient disease, MEK + checkpoint inhibitor combinations, and adjuvant immunotherapy trials for high-risk (Class 2) uveal melanoma. For retinoblastoma: IAC protocol refinement trials, intravitreal chemotherapy trials for vitreous seeding, and survivorship and second malignancy prevention trials for RB1 germline carriers. For conjunctival melanoma: participation in mucosal melanoma consortia trials. Molecular profiling — particularly GNAQ/GNA11, BAP1, HLA typing, and BRAF status — is key to determining which trials are relevant for each patient.

Yes. CancerFax supports patients with eye and adnexa cancer in accessing specialist ocular oncology second opinions, proton therapy eligibility and referral for uveal melanoma, retinoblastoma specialist centre access including IAC programmes, molecular profiling coordination (GNAQ/GNA11, BAP1, RB1, BRAF, HLA-A*02:01), tebentafusp eligibility assessment, and clinical trial identification based on subtype and molecular profile. For rare subtypes — lacrimal gland carcinoma, orbital rhabdomyosarcoma, and sebaceous carcinoma — CancerFax helps identify specialist centres with appropriate expertise. Share your medical reports and imaging with our team to begin.